[1] Stintzing et al., Phase III FIRE-4 study (AIO KRK-0114): Influence of Baseline Liquid Biopsy Results in First-Line Treatment Efficacy of FOLFIRI/ Cetuximab in Patients with Tissue RAS-WT mCRC, ASCO 2023; Abstract 3507. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.3507 [12.09.2023]

[2] Tie et al.: Circulating Tumor DNA Analysis Detects Minimal Residual Disease and Predicts Recurrence in Patients with Atage II Colon Cancer. Science Translational Medicine 2016;8(346):346ra92: https://www.science.org/doi/abs/10.1126/scitranslmed.aaf6219 [12.09.2023]

[3] Reinert et al.: Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stage I to III Colorectal Cancer. Jama Oncology 2019;5(8):1124–1131. https://jamanetwork.com/journals/jamaoncology/article-abstract/2733132 [12.09.2023]

[4] S1-Leitlinie Tumorgenetik aus 2021: https://register.awmf.org/assets/guidelines/078-017l_S1_Tumorgenetik-Genetische-Diagnostik-bei-malignen-Erkrankungen_2022-03.pdf; S3-Leitlinie Kolorektales Karzinom aus 2017: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Kolorektales_Karzinom/Version_2/LL_KRK_Langversion_2.1.pdf ; Empfehlungen der European Society for Medical Oncology (ESMO) aus 2022: https://www.annalsofoncology.org/article/S0923-7534(22)01721-5/fulltext [12.09.2023]

[5] DYNAMIC-Studie: Tie et al.: Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England Journal of Medicine 2022;386(24):2261–2272. https://www.nejm.org/doi/full/10.1056/NEJMoa2200075 [12.09.2023]